Название продукции:methyl hex-5-ynoate

IUPAC Name:methyl hex-5-ynoate

CAS:77758-51-1
Молекулярная формула:C7H10O2
Чистота:95%
Номер в каталоге:CM194621
Молекулярная масса:126.16

Упаковочная единица Доступно для заказа Цена ($) Количество
CM194621-5g in stock ƃȅ
CM194621-25g in stock ǫŞǫ

Только для использования в НИОКР..

Форма запроса

   refresh    

Информация о продукции

Номер CAS:77758-51-1
Молекулярная формула:C7H10O2
Точка плавления:-
Smiles-код:C#CCCCC(OC)=O
Плотность:
Номер в каталоге:CM194621
Молекулярная масса:126.16
Точка кипения:
Номер Mdl:MFCD00671366
Хранение:Store at 2-8°C.

Category Infos

Aliphatic Chain Compounds
Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

Column Infos

Lanifibranor
Recently, Inventiva announced positive results of its interim analysis of the Phase II, Proof-of-Concept clinical trial, LEGEND, evaluating lanifibranor in combination with empagliflozin in patients with MASH/NASH and poorly controlled Type 2 Diabetes (T2D). The study achieved the primary efficacy endpoint. Lanifibranor is an orally-available small molecule pan PPAR agonist with a -wellbalanced- activation of PPARα and PPARδ, and a partial activation of PPARγ. Lanifibranor acts to induce anti fibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body.